NephroGenex - Innovative Therapies for Kidney Disease

	PRODUCT CANDIDATE

Pyridorin™

NephroGenex acquired commercial rights to Pyridorin™ and is currently investigating the safety and efficacy of Pyridorin™ therapy for kidney diseases in which pathogenic oxidative chemistries are an established causative factor. These include diabetic nephropathy and acute renal failure.

Pyridorin™ Fast Facts:

Name - Pyridorin™ (pyridoxamine dihydrochloride)
History - Rights acquired from BioStratum
Active Ingredient - Pyridoxamine dihydrochloride
Target - Intercepting and preventing pathogenic oxidative chemistries
Indication - Kidney disease in patients with type 2 diabetes
Status - Completed two phase 2 clinical trials demonstrating safety and a promising treatment effect; newly launched Phase IIb clinical trial to confirm findings and to establish new surrogate marker for approval
Market Potential - approximately 2.8 M patients with overt diabetic nephropathy in the U.S; approximately 3.5 M have earlier microalbuminuria
Commercialization - NephroGenex will seek a partner for Phase 3 development and commercialization
Anticipated Market Entry Date - 2014

Diabetic Nephropathy

Pyridorin™ targets a broad range of pathogenic oxidative chemistries, including advanced glycation end-products, toxic carbonyls, and reactive oxygen species that develop in patients with diabetes and are considered a principal causative factor in the development of diabetic microvascular disease. Hyperglycemia-induced microvascular disease is the fundamental cause of diabetic complications, including nephropathy, retinopathy, and neuropathy.

Pyridorin™ has been evaluated in two Phase 2 clinical trials and has demonstrated in both a significant treatment effect in retarding the progression of diabetic nephropathy. NephroGenex is continuing the clinical study of Pyridorin™ for diabetic overt nephropathy, and the Company has launched a new Phase 2b trial (PYR-210), which is examining the safety and efficacy of Pyridorin™ therapy in slowing the progression of overt nephropathy in patients with type 2 diabetes.

Other Indications

NephroGenex is also studying the application of Pyridorin™ to specific types of acute renal failure in which pathogenic oxidative chemistries have been identified as likely causative factors in the onset and progression of this condition. These include contrast-dye-induced acute renal failure and ischemia-reperfusion acute renal injury, which can arise in cardiac and vascular surgeries.